Clinical pharmacokinetic monitoring of midazolam in critically ill patients

Pharmacotherapy

Volumn 27, Issue 3, 2007, Pages 389-398

  Spina, Sean P ^a,b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ROYAL COLUMBIAN HOSPITAL   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Critical care; Intensive care unit; Midazolam; Sedation; Therapeutic drug monitoring

Indexed keywords

1,4 DIHYDROXYMIDAZOLAM; ALPHA1 HYDROXYMIDAZOLAM; ALPHA4 HYDROXYMIDAZOLAM; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450 3A4; MIDAZOLAM; UNCLASSIFIED DRUG;

ARTIFICIAL VENTILATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CRITICAL ILLNESS; DECISION MAKING; DRUG BLOOD LEVEL; DRUG CLEARANCE; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN TISSUE; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; NERVOUS SYSTEM INJURY; PATIENT MONITORING; REVIEW; SEDATION; VALIDATION PROCESS;

EID: 33847254988     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.3.389     Document Type: Review

References (43)

1. Riker RR, Fraser GL, Simmons LE, Wilkins ML. Validating the sedation-agitation scale with the bispectral index and visual analog scale in adult ICU patients after cardiac surgery. Intensive Care Med 2001;27;853-8.
2. Bolon M, Bastien O, Flamens C, Paulus S, Boulieu R. Midazolam disposition in patients undergoing continuous venovenous hemodialysis. J Clin Pharmacol 2001;41:959-62.
3. Burns AM, Shelly MP, Park GR. The use of sedative agents in critically ill patients. Drugs 1992;43:507-15.
4. Fragen RJ. Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units. Clin Ther 1997;19:405-19; discussion 367-8.
5. Arcangeli A, Antonelli M, Mignani V, Sandroni C. Sedation in PACU: the role of benzodiazepines. Curr Drug Targets 2005;6:745-8.
6. Bremer F, Reulbach U, Schwilden H, Schuttler J. Midazolam therapeutic drug monitoring in intensive care sedation: a 5-year survey. Ther Drug Monit 2004;26:643-9.
7. Bauer TM, Ritz R, Haberthur C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995;346:145-7.
8. Oldenhof H, de Jong M, Steenhoek A, Janknegt R. Clinical pharmacokinetics of midazolam in intensive care patients: a wide interpatient variability? Clin Pharmacol Ther 1988;43:263-9.
9. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51:715-28.
10. Bouton V, Bourget P, Lesne-Hulin A, et al. Influence of acute renal failure on FPIA rapid serum assay of midazolam and its main metabolite. Int J Clin Pharmacol Ther 1997;35:531-8.
11. Hirata K, Matsumoto Y, Kurokawa A, et al. Possibility of influence of midazolam sedation on the diagnosis of brain death: concentrations of active metabolites after cessation of midazolam. Yakugaku Zasshi 2003;123:811-15.
12. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119-41.
13. Wills RJ, Khoo KC, Soni PP, Patel IH. Increased volume of distribution prolongs midazolam half-life. Br J Clin Pharmacol 1990;29:269-72.
14. Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolise midazolam. Anaesthesia 1987;42:619-26.
15. Boulieu R, Lehmann B, Salord F, Fisher C, Morlet D. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients. Eur J Drug Metab Pharmacokinet 1998;23:255-8.
16. Riker RR, Fraser GL. Monitoring sedation, agitation, analgesia, neuromuscular blockade, and delirium in adult ICU patients. Semin Respir Crit Care Med 2001;22:189-98.
17. Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadolone. Br Med J 1974;2:656-9.
18. Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond agitation-sedation scale (RASS). JAMA 2003;289:2983-91.
19. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond agitation-sedation scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002;166:1338-44.
20. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342:1471-7.
21. Walson PD. Therapeutic drug monitoring in special populations. Clin Chem 1998;44:415-19.
22. Ensom MH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet 1998;34:265-79.
23. De Kroon IF, Langendijk PN, De Goede PN. Simultaneous determination of midazolam and its three hydroxy metabolites in human plasma by electron-capture gas chromatography without derivatization. J Chromatogr 1989;491:107-16.
24. Vletter AA, Burm AG, Breimer LT, Spierdijk J. High-performance liquid chromatographic assay to determine midazolam and flumazenil simultaneously in human plasma. J Chromatogr 1990;530:177-85.
25. Van Brandt N, Hantson P, Mahieu P, Verbeeck RK. A rapid high-performance liquid chromatographic method for the measurement of midazolam plasma concentrations during long-term infusion in ICU patients. Ther Drug Monit 1997;19:352-7.
26. Carrillo JA, Ramos SI, Agundez JA, Martinez C, Benitez J. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther Drug Monit 1998;20:319-24.
27. Muchohi SN, Ward SA, Preston L, Newton CR, Edwards G, Kokwaro GO. Determination of midazolam and its major metabolite 1′-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. J Chromatogr B Analyt Technol Biomed Life Sci 2005;821:1-7.
28. Frerichs VA, Zaranek C, Haas CE. Analysis of omeprazole, midazolam and hydroxy-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;824:71-80.
29. Quintela O, Cruz A, Concheiro M, de Castro A, Lopez-Rivadulla M. A sensitive, rapid and specific determination of midazolam in human plasma and saliva by liquid chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 2004;18:2976-82.
30. Bourget P, Bouton V, Lesne-Hulin A, et al. Comparison of high-performance liquid chromatography and polyclonal fluorescence polarization immunoassay for the monitoring of midazolam in the plasma of intensive care unit patients. Ther Drug Monit 1996;18:610-19.
31. Dirksen MS, Vree TB, Driessen JJ. Clinical pharmacokinetics of long-term infusion of midazolam in critically ill patients: preliminary results. Anaesth Intensive Care 1987;15:440-4.
32. Albrecht S, Ihmsen H, Hering W, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999;65:630-9.
33. Devlin JW, Fraser GL, Kanji S, Riker RR. Sedation assessment in critically ill adults. Ann Pharmacother 2001;35:1624-32.
34. McKenzie CA, McKinnon W, Naughton DP, et al. Differentiating midazolam over-sedation from neurological damage in the intensive care unit. Crit Care 2005;9:R32-6.
35. Frenzel D, Greim CA, Sommer C, Bauerle K, Roewer N. Is the bispectral index appropriate for monitoring the sedation level of mechanically ventilated surgical ICU patients? Intensive Care Med 2002;28:178-83.
36. Fraser GL, Riker RR. Bispectral index monitoring in the intensive care unit provides more signal than noise. Pharmacotherapy 2005;25(5 pt 2):19S-27.
37. Doi M, Ikeda K. Age related changes in pharmacodynamics and pharmacokinetics of midazolam during sedation in ICU patients [abstr]. Anesthesiology 1994;81:A259.
38. Vinik HR, Reves JG, Greenblatt DJ, Abernethy DR, Smith LR. The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 1983;59:390-4.
39. Driessen JJ, Vree TB, Guelen PJ. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol Belg 1991;42:149-55.
40. Swart EL, de Jongh J, Zuideveld KP, Danhof M, Thijs LG, Strack van Schijndel RJ. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis 2005;45:360-71.
41. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med 1998;26:947-56.
42. Calvo R, Suarez E, Rodriguez-Sasiain JM, Martinez I. The influence of renal failure on the kinetics of intravenous midazolam: an "in vitro" and "in vivo" study. Res Commun Chem Pathol Pharmacol 1992;78:311-20.
43. Kollef MH, Levy NT, Ahrens TS, Schaiff R, Prentice D, Sherman G. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest 1998;114:541-8.